Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.31 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.31 |
| ▸ | PNMT | P11086 | 1/20 | 0.31 |
| ▸ | TP53 | P04637 | 1/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.31 |
| ▸ | FEN1 | P39748 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | GLA | P06280 | 1/20 | 0.31 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.30 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23432951 | 0.82 | EIF4A3 (0.36) | LMNACYP1A2CYP3A4CYP2D6NFKB1 | |
| SCHEMBL20223454 | 0.80 | EIF4A3 (0.35) | LMNACYP1A2CYP3A4HTTALOX5AP | |
| SCHEMBL21852127 | 0.80 | ALDH1A1 (0.35) | LMNACYP1A2CYP3A4CYP2D6NFKB1 | |
| SCHEMBL21191253 | 0.78 | GABRA1 (0.37) | LMNATP53HTTGABRA1GABRB1 | |
| SCHEMBL12534165 | 0.78 | LMNA (0.33) | LMNACYP1A2CYP3A4CYP2D6NFKB1 | |
| SCHEMBL15012977 | 0.77 | ALOX5AP (0.34) | LMNACYP3A4TP53ALOX5APFEN1 | |
| SCHEMBL10592381 | 0.77 | FAAH (0.33) | LMNACYP1A2CYP3A4ALOX5APFEN1 | |
| SCHEMBL12604300 | 0.77 | LMNA (0.35) | LMNAGABRA1GABRB1 | |
| SCHEMBL12533352 | 0.75 | P2RX7 (0.31) | GABRA1GABRB1 | |
| SCHEMBL27317473 | 0.74 | GABRA1 (0.42) | LMNACYP1A2CYP3A4CYP2D6NFKB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7956068-B2 | Inhibitors of human immunodeficiency virus replication | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-06-07 | — | — | US | disclosed |
| US-7956068-B2 | Inhibitors of human immunodeficiency virus replication | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-06-07 | — | — | US | disclosed |
| US-20100305115-A1 | INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION | BOEHRINGER INGLEHEIM INTERNATIONAL GMBH (DE) | 2010-12-02 | — | — | US | disclosed |
| US-20100305115-A1 | INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION | BOEHRINGER INGLEHEIM INTERNATIONAL GMBH (DE) | 2010-12-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100305115-A1 | INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION | CCNY, RTF2, POLR2E | LMNA 2685/4885CYP1A2 1818/4885CYP3A4 786/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.